Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant AK104 + Chemo for Fertility-Sparing Cervical Cancer
NCT06209294Phase 2Recruiting
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in Cervical Cancer (CC). Started Sep 2023; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06209294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06209294.